Abstract
To date, numerous genetic and epigenetic studies have been performed and provided a crucial step forward in our understanding of the pathogenesis of rheumatic diseases. However, most of the recent advances in the treatment of rheumatic diseases including biological therapies are not based on or even discrepant from these genetic and epigenetic findings. For example, tumor necrosis factor inhibitors are quite successful in the treatment of rheumatoid arthritis (RA), Behçet’s disease (BD), ankylosing spondylitis (AS) and psoriatic arthritis (PsA) but not in that of systemic lupus erythematosus (SLE), systemic sclerosis (SSc), Sjögren’s syndrome (SS) and antineutrophil cytoplasmic antibody-associated vasculitis (AAV), conversely, RA shares genetic backgrounds more with SLE, SSc, SS and AAV than BD, AS and PsA. In this review, we briefly highlight the findings from recent genetic and epigenetic studies and discuss what needs to be studied to provide a novel, more efficacious management of rheumatic diseases.
Similar content being viewed by others
References
Generali E, Ceribelli A, Stazi MA, Selmi C (2017) Lessons learned from twins in autoimmune and chronic inflammatory diseases. J Autoimmun 83:51–61
Okada Y, Wu D, Trynka G, Raj T, Terao C, Ikari K et al (2014) Genetics of rheumatoid arthritis contributes to biology and drug discovery. Nature 506(7488):376–381
Wen L, Zhu C, Zhu Z, Yang C, Zheng X, Liu L et al (2018) Exome-wide association study identifies four novel loci for systemic lupus erythematosus in Han Chinese population. Ann Rheum Dis 77(3):417–422
Terao C, Kawaguchi T, Dieude P, Varga J, Kuwana M, Hudson M et al (2017) Transethnic meta-analysis identifies GSDMA and PRDM1 as susceptibility genes to systemic sclerosis. Ann Rheum Dis 76(6):1150–1158
Lessard CJ, Li H, Adrianto I, Ice JA, Rasmussen A, Grundahl KM et al (2013) Variants at multiple loci implicated in both innate and adaptive immune responses are associated with Sjogren’s syndrome. Nat Genet 45(11):1284–1292
Merkel PA, Xie G, Monach PA, Ji X, Ciavatta DJ, Byun J et al (2017) Identification of functional and expression polymorphisms associated with risk for antineutrophil cytoplasmic autoantibody-associated vasculitis. Arthritis Rheumatol 69(5):1054–1066
Takeuchi M, Mizuki N, Meguro A, Ombrello MJ, Kirino Y, Satorius C et al (2017) Dense genotyping of immune-related loci implicates host responses to microbial exposure in Behcet’s disease susceptibility. Nat Genet 49(3):438–443
International Genetics of Ankylosing Spondylitis C, Cortes A, Hadler J, Pointon JP, Robinson PC, Karaderi T et al (2013) Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci. Nat Genet 45(7):730–738
Stuart PE, Nair RP, Tsoi LC, Tejasvi T, Das S, Kang HM et al (2015) Genome-wide association analysis of psoriatic arthritis and cutaneous psoriasis reveals differences in their genetic architecture. Am J Hum Genet 97(6):816–836
Suzuki A, Yamada R, Chang X, Tokuhiro S, Sawada T, Suzuki M et al (2003) Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis. Nat Genet 34(4):395–402
Kirino Y, Zhou Q, Ishigatsubo Y, Mizuki N, Tugal-Tutkun I, Seyahi E et al (2013) Targeted resequencing implicates the familial Mediterranean fever gene MEFV and the toll-like receptor 4 gene TLR4 in Behcet disease. Proc Natl Acad Sci USA 110(20):8134–8139
Adrianto I, Wen F, Templeton A, Wiley G, King JB, Lessard CJ et al (2011) Association of a functional variant downstream of TNFAIP3 with systemic lupus erythematosus. Nat Genet 43(3):253–258
Padyukov L, Seielstad M, Ong RT, Ding B, Ronnelid J, Seddighzadeh M et al (2011) A genome-wide association study suggests contrasting associations in ACPA-positive versus ACPA-negative rheumatoid arthritis. Ann Rheum Dis 70(2):259–265
Surolia I, Pirnie SP, Chellappa V, Taylor KN, Cariappa A, Moya J et al (2010) Functionally defective germline variants of sialic acid acetylesterase in autoimmunity. Nature 466(7303):243–247
Jeffries MA, Dozmorov M, Tang Y, Merrill JT, Wren JD, Sawalha AH (2011) Genome-wide DNA methylation patterns in CD4 + T cells from patients with systemic lupus erythematosus. Epigenetics 6(5):593–601
Quddus J, Johnson KJ, Gavalchin J, Amento EP, Chrisp CE, Yung RL et al (1993) Treating activated CD4 + T cells with either of two distinct DNA methyltransferase inhibitors, 5-azacytidine or procainamide, is sufficient to cause a lupus-like disease in syngeneic mice. J Clin Invest 92(1):38–53
Lu Q, Wu A, Richardson BC (2005) Demethylation of the same promoter sequence increases CD70 expression in lupus T cells and T cells treated with lupus-inducing drugs. J Immunol 174(10):6212–6219
Lu Q, Wu A, Tesmer L, Ray D, Yousif N, Richardson B (2007) Demethylation of CD40LG on the inactive X in T cells from women with lupus. J Immunol 179(9):6352–6358
Deng C, Kaplan MJ, Yang J, Ray D, Zhang Z, McCune WJ et al (2001) Decreased Ras-mitogen-activated protein kinase signaling may cause DNA hypomethylation in T lymphocytes from lupus patients. Arthritis Rheum 44(2):397–407
Yasuda S, Stevens RL, Terada T, Takeda M, Hashimoto T, Fukae J et al (2007) Defective expression of Ras guanyl nucleotide-releasing protein 1 in a subset of patients with systemic lupus erythematosus. J Immunol 179(7):4890–4900
Pan W, Zhu S, Yuan M, Cui H, Wang L, Luo X et al (2010) MicroRNA-21 and microRNA-148a contribute to DNA hypomethylation in lupus CD4 + T cells by directly and indirectly targeting DNA methyltransferase 1. J Immunol 184(12):6773–6781
Zhao S, Wang Y, Liang Y, Zhao M, Long H, Ding S et al (2011) MicroRNA-126 regulates DNA methylation in CD4 + T cells and contributes to systemic lupus erythematosus by targeting DNA methyltransferase 1. Arthritis Rheum 63(5):1376–1386
Glossop JR, Emes RD, Nixon NB, Packham JC, Fryer AA, Mattey DL et al (2016) Genome-wide profiling in treatment-naive early rheumatoid arthritis reveals DNA methylome changes in T and B lymphocytes. Epigenomics 8(2):209–224
Ding W, Pu W, Wang L, Jiang S, Zhou X, Tu W et al (2017) Genome-wide DNA methylation analysis in systemic sclerosis reveals hypomethylation of interferon-associated genes in CD4(+) and CD8(+) T cells. J Invest Dermatol. https://doi.org/10.1016/j.jid.2017.12.003
Altorok N, Coit P, Hughes T, Koelsch KA, Stone DU, Rasmussen A et al (2014) Genome-wide DNA methylation patterns in naive CD4 + T cells from patients with primary Sjogren’s syndrome. Arthritis Rheumatol 66(3):731–739
Karouzakis E, Gay RE, Michel BA, Gay S, Neidhart M (2009) DNA hypomethylation in rheumatoid arthritis synovial fibroblasts. Arthritis Rheum 60(12):3613–3622
Altorok N, Tsou PS, Coit P, Khanna D, Sawalha AH (2015) Genome-wide DNA methylation analysis in dermal fibroblasts from patients with diffuse and limited systemic sclerosis reveals common and subset-specific DNA methylation aberrancies. Ann Rheum Dis 74(8):1612–1620
Charras A, Konsta OD, Le Dantec C, Bagacean C, Kapsogeorgou EK, Tzioufas AG et al (2017) Cell-specific epigenome-wide DNA methylation profile in long-term cultured minor salivary gland epithelial cells from patients with Sjogren’s syndrome. Ann Rheum Dis 76(3):625–628
Huber LC, Brock M, Hemmatazad H, Giger OT, Moritz F, Trenkmann M et al (2007) Histone deacetylase/acetylase activity in total synovial tissue derived from rheumatoid arthritis and osteoarthritis patients. Arthritis Rheum 56(4):1087–1093
Angiolilli C, Kabala PA, Grabiec AM, Van Baarsen IM, Ferguson BS, Garcia S et al (2017) Histone deacetylase 3 regulates the inflammatory gene expression programme of rheumatoid arthritis fibroblast-like synoviocytes. Ann Rheum Dis 76(1):277–285
Joosten LA, Leoni F, Meghji S, Mascagni P (2011) Inhibition of HDAC activity by ITF2357 ameliorates joint inflammation and prevents cartilage and bone destruction in experimental arthritis. Mol Med 17(5–6):391–396
Vojinovic J, Damjanov N, D’Urzo C, Furlan A, Susic G, Pasic S et al (2011) Safety and efficacy of an oral histone deacetylase inhibitor in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 63(5):1452–1458
Klein K, Kabala PA, Grabiec AM, Gay RE, Kolling C, Lin LL et al (2016) The bromodomain protein inhibitor I-BET151 suppresses expression of inflammatory genes and matrix degrading enzymes in rheumatoid arthritis synovial fibroblasts. Ann Rheum Dis 75(2):422–429
Mele DA, Salmeron A, Ghosh S, Huang HR, Bryant BM, Lora JM (2013) BET bromodomain inhibition suppresses TH17-mediated pathology. J Exp Med 210(11):2181–2190
de Andres MC, Perez-Pampin E, Calaza M, Santaclara FJ, Ortea I, Gomez-Reino JJ et al (2015) Assessment of global DNA methylation in peripheral blood cell subpopulations of early rheumatoid arthritis before and after methotrexate. Arthritis Res Ther 17:233
Liu Y, Aryee MJ, Padyukov L, Fallin MD, Hesselberg E, Runarsson A et al (2013) Epigenome-wide association data implicate DNA methylation as an intermediary of genetic risk in rheumatoid arthritis. Nat Biotechnol 31(2):142–147
Gorelik GJ, Yarlagadda S, Patel DR, Richardson BC (2012) Protein kinase Cdelta oxidation contributes to ERK inactivation in lupus T cells. Arthritis Rheum 64(9):2964–2974
Sunahori K, Nagpal K, Hedrich CM, Mizui M, Fitzgerald LM, Tsokos GC (2013) The catalytic subunit of protein phosphatase 2A (PP2Ac) promotes DNA hypomethylation by suppressing the phosphorylated mitogen-activated protein kinase/extracellular signal-regulated kinase (ERK) kinase (MEK)/phosphorylated ERK/DNMT1 protein pathway in T-cells from controls and systemic lupus erythematosus patients. J Biol Chem 288(30):21936–21944
Author information
Authors and Affiliations
Contributions
MK wrote the manuscript. SY and TA critically reviewed and revised the manuscript.
Corresponding author
Ethics declarations
Conflict of interest
Author MK declares that he has no conflict of interest. Author SY declares that he has no conflict of interest. Author TA declares that he has no conflict of interest.
Ethical approval
This article does not contain any studies with human participants or animals performed by any of the authors.
Rights and permissions
About this article
Cite this article
Kato, M., Yasuda, S. & Atsumi, T. The role of genetics and epigenetics in rheumatic diseases: are they really a target to be aimed at?. Rheumatol Int 38, 1333–1338 (2018). https://doi.org/10.1007/s00296-018-4026-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00296-018-4026-0